Buchumschlag

Therapeutic options in recurrent glioblastoma: an update

Introduction - Standards of care are not yet defined in recurrent glioblastoma. - Methods - We reviewed the literature on clinical trials for recurrent glioblastoma available in PubMed and American Society of Clinical Oncology (ASCO) abstracts until June 2015. - Results - Evidence is limited due to...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Seystahl, Katharina Gertrud (VerfasserIn) , Wick, Wolfgang (VerfasserIn) , Weller, Michael (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 21 January 2016
In: Critical reviews in oncology, hematology
Year: 2016, Jahrgang: 99, Pages: 389-408
ISSN:1879-0461
DOI:10.1016/j.critrevonc.2016.01.018
Online-Zugang:Verlag, Volltext: https://doi.org/10.1016/j.critrevonc.2016.01.018
Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S104084281630018X
Volltext
Verfasserangaben:Katharina Seystahl, Wolfgang Wick, Michael Weller

MARC

LEADER 00000caa a2200000 c 4500
001 169198650X
003 DE-627
005 20220818011144.0
007 cr uuu---uuuuu
008 200310s2016 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.critrevonc.2016.01.018  |2 doi 
035 |a (DE-627)169198650X 
035 |a (DE-599)KXP169198650X 
035 |a (OCoLC)1341309968 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Seystahl, Katharina Gertrud  |e VerfasserIn  |0 (DE-588)142822663  |0 (DE-627)640138756  |0 (DE-576)333576705  |4 aut 
245 1 0 |a Therapeutic options in recurrent glioblastoma  |b an update  |c Katharina Seystahl, Wolfgang Wick, Michael Weller 
264 1 |c 21 January 2016 
300 |a 20 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 10.03.2020 
520 |a Introduction - Standards of care are not yet defined in recurrent glioblastoma. - Methods - We reviewed the literature on clinical trials for recurrent glioblastoma available in PubMed and American Society of Clinical Oncology (ASCO) abstracts until June 2015. - Results - Evidence is limited due to the paucity of randomized controlled studies. Second surgery or re-irradiation are options for selected patients. Alkylating chemotherapy such as nitrosoureas or temozolomide and the vascular endothelial growth factor (VEGF) antibody, bevacizumab, exhibit comparable single agent activity. Phase III data exploring the benefit of combining bevacizumab and lomustine are emerging. Novel approaches in the fields of targeted therapy, immunotherapy, and tumor metabolism are coming forward. Several biomarkers are being explored, but, except for O6-methylguanine DNA methyltransferase (MGMT) promoter methylation, none has assumed a role in clinical practice. - Conclusion - Proper patient selection, development of predictive biomarkers and randomized controlled studies are required to develop evidence-based concepts for recurrent glioblastoma. 
650 4 |a Bevacizumab 
650 4 |a Glioblastoma 
650 4 |a Immunotherapy 
650 4 |a MGMT 
650 4 |a Nitrosourea 
650 4 |a Temozolomide 
700 1 |a Wick, Wolfgang  |d 1970-  |e VerfasserIn  |0 (DE-588)120297736  |0 (DE-627)080586929  |0 (DE-576)186221320  |4 aut 
700 1 |a Weller, Michael  |d 1962-  |e VerfasserIn  |0 (DE-588)130838039  |0 (DE-627)506356701  |0 (DE-576)29836834X  |4 aut 
773 0 8 |i Enthalten in  |t Critical reviews in oncology, hematology  |d Amsterdam [u.a.] : Elsevier Science, 1983  |g 99(2016), Seite 389-408  |h Online-Ressource  |w (DE-627)320649024  |w (DE-600)2025731-4  |w (DE-576)094108137  |x 1879-0461  |7 nnas  |a Therapeutic options in recurrent glioblastoma an update 
773 1 8 |g volume:99  |g year:2016  |g pages:389-408  |g extent:20  |a Therapeutic options in recurrent glioblastoma an update 
856 4 0 |u https://doi.org/10.1016/j.critrevonc.2016.01.018  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u http://www.sciencedirect.com/science/article/pii/S104084281630018X  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20200310 
993 |a Article 
994 |a 2016 
998 |g 120297736  |a Wick, Wolfgang  |m 120297736:Wick, Wolfgang  |d 910000  |d 911100  |e 910000PW120297736  |e 911100PW120297736  |k 0/910000/  |k 1/910000/911100/  |p 2 
999 |a KXP-PPN169198650X  |e 3605579396 
BIB |a Y 
SER |a journal 
JSO |a {"origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"21 January 2016"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"relHost":[{"recId":"320649024","pubHistory":["1.1983/84 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"1983","publisherPlace":"Amsterdam [u.a.]","dateIssuedDisp":"1983-","publisher":"Elsevier Science"}],"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"part":{"extent":"20","year":"2016","pages":"389-408","text":"99(2016), Seite 389-408","volume":"99"},"id":{"eki":["320649024"],"zdb":["2025731-4"],"issn":["1879-0461"]},"title":[{"title":"Critical reviews in oncology, hematology","title_sort":"Critical reviews in oncology, hematology"}],"disp":"Therapeutic options in recurrent glioblastoma an updateCritical reviews in oncology, hematology","note":["Gesehen am 04.02.20"]}],"person":[{"given":"Katharina Gertrud","display":"Seystahl, Katharina Gertrud","role":"aut","family":"Seystahl","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Wick","given":"Wolfgang","role":"aut","display":"Wick, Wolfgang"},{"family":"Weller","roleDisplay":"VerfasserIn","role":"aut","display":"Weller, Michael","given":"Michael"}],"name":{"displayForm":["Katharina Seystahl, Wolfgang Wick, Michael Weller"]},"physDesc":[{"extent":"20 S."}],"note":["Gesehen am 10.03.2020"],"recId":"169198650X","id":{"eki":["169198650X"],"doi":["10.1016/j.critrevonc.2016.01.018"]},"title":[{"title":"Therapeutic options in recurrent glioblastoma","title_sort":"Therapeutic options in recurrent glioblastoma","subtitle":"an update"}]} 
SRT |a SEYSTAHLKATHERAPEUTI2120 

Ähnliche Einträge